UBS Group AG boosted its position in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 283.2% during the first quarter, Holdings Channel reports. The fund owned 13,767 shares of the specialty pharmaceutical company’s stock after buying an additional 10,174 shares during the period. UBS Group AG’s holdings in Collegium Pharmaceutical were worth $139,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in COLL. NBW Capital LLC increased its stake in Collegium Pharmaceutical by 1.8% in the first quarter. NBW Capital LLC now owns 62,030 shares of the specialty pharmaceutical company’s stock worth $624,000 after buying an additional 1,114 shares during the last quarter. Nationwide Fund Advisors increased its stake in Collegium Pharmaceutical by 16.4% in the first quarter. Nationwide Fund Advisors now owns 10,087 shares of the specialty pharmaceutical company’s stock worth $101,000 after buying an additional 1,422 shares during the last quarter. American International Group Inc. increased its stake in Collegium Pharmaceutical by 27.8% in the first quarter. American International Group Inc. now owns 9,948 shares of the specialty pharmaceutical company’s stock worth $100,000 after buying an additional 2,163 shares during the last quarter. Bank of New York Mellon Corp increased its stake in Collegium Pharmaceutical by 6.1% in the first quarter. Bank of New York Mellon Corp now owns 65,305 shares of the specialty pharmaceutical company’s stock worth $656,000 after buying an additional 3,775 shares during the last quarter. Finally, Teachers Advisors LLC increased its stake in Collegium Pharmaceutical by 18.1% in the fourth quarter. Teachers Advisors LLC now owns 25,437 shares of the specialty pharmaceutical company’s stock worth $396,000 after buying an additional 3,892 shares during the last quarter. Institutional investors own 82.27% of the company’s stock.

Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) traded up 1.647% during mid-day trading on Friday, reaching $10.185. The company’s stock had a trading volume of 65,318 shares. The company’s 50-day moving average is $12.19 and its 200 day moving average is $11.98. The firm’s market cap is $301.13 million. Collegium Pharmaceutical, Inc. has a 12 month low of $7.37 and a 12 month high of $20.55.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings data on Wednesday, August 9th. The specialty pharmaceutical company reported ($0.72) EPS for the quarter, beating the consensus estimate of ($0.81) by $0.09. The firm had revenue of $3.56 million during the quarter, compared to the consensus estimate of $4.07 million. Collegium Pharmaceutical had a negative net margin of 1,319.39% and a negative return on equity of 91.05%. On average, equities analysts anticipate that Collegium Pharmaceutical, Inc. will post ($3.00) EPS for the current year.

COPYRIGHT VIOLATION WARNING: “UBS Group AG Increases Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)” was originally posted by Watch List News and is the property of of Watch List News. If you are reading this report on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this report can be viewed at https://www.watchlistnews.com/ubs-group-ag-increases-position-in-collegium-pharmaceutical-inc-nasdaqcoll/1475159.html.

A number of analysts recently weighed in on the company. BidaskClub downgraded Collegium Pharmaceutical from a “hold” rating to a “sell” rating in a report on Friday, August 4th. Piper Jaffray Companies set a $14.00 price objective on Collegium Pharmaceutical and gave the company a “buy” rating in a report on Tuesday, July 25th. Zacks Investment Research downgraded Collegium Pharmaceutical from a “hold” rating to a “sell” rating in a report on Tuesday, July 11th. ValuEngine upgraded Collegium Pharmaceutical from a “strong sell” rating to a “sell” rating in a report on Thursday, June 22nd. Finally, Janney Montgomery Scott restated a “buy” rating and issued a $25.00 price objective on shares of Collegium Pharmaceutical in a report on Monday, June 12th. Three equities research analysts have rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $21.33.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.

Want to see what other hedge funds are holding COLL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Collegium Pharmaceutical, Inc. (NASDAQ:COLL).

Institutional Ownership by Quarter for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.